Barclays’s Biocept, Inc. BIOC Stock Holding History

Barclays’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-788	Closed	-$63K	–	6425
2020 Q1	$63K	Buy	+788	New	+$80.6K	﹤0.01%	5093
2019 Q4	–	Hold	0	–	–	–	6974
2019 Q3	–	Sell	-1	Closed	-$288	–	7272
2019 Q2	$0	Sell	1 -100	-99%	-$31.7K	﹤0.01%	7405
2019 Q1	$35K	Buy	+101	New	+$40.9K	﹤0.01%	6109
2018 Q4	–	Hold	0	–	–	–	7485
2018 Q3	–	Sell	-61	Closed	-$109K	–	7491
2018 Q2	$109K	Buy	61 +32	+110%	+$64.8K	﹤0.01%	5190
2018 Q1	$76K	Buy	+29	New	+$109K	﹤0.01%	5589
2015 Q4	–	Sell	-1	Closed	-$43K	–	6746
2015 Q3	$43K	Buy	+1	New	+$62.5K	﹤0.01%	5097

Other funds holding BIOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Barclays's BIOC Position: Q2 2020 in Review

Barclays sold out of Biocept, Inc. (BIOC) in Q2 2020, closing a stake of 788 shares — an estimated $63K sold.

Barclays first reported a position in BIOC in Q3 2015 and held it in 6 quarters. The position peaked at $109K in Q2 2018. 20 funds tracked by Wall St. Rank hold BIOC as of Q2 2020.

Barclays reported no remaining Biocept, Inc. position as of Q2 2020 after selling out during the quarter.
Barclays sold 788 Biocept, Inc. shares in Q2 2020, an estimated $63K.
Barclays first reported a position in Biocept, Inc. in Q3 2015 and held it in 6 quarters.
Barclays's Biocept, Inc. position peaked at $109K in Q2 2018.
20 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2020.

Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.